Ligand Pharmaceuticals, Inc. (LGND)
299.00
+5.19
(+1.77%)
USD |
NASDAQ |
Nov 18, 16:00
299.00
0.00 (0.00%)
After-Hours: 20:00
Ligand Pharmaceuticals Enterprise Value : 6.579B for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 6.579B |
| November 16, 2026 | 6.737B |
| November 13, 2026 | 6.879B |
| November 12, 2026 | 7.028B |
| November 11, 2026 | 7.040B |
| November 10, 2026 | 6.986B |
| November 09, 2026 | 6.986B |
| November 06, 2026 | 6.827B |
| November 05, 2026 | 6.683B |
| November 04, 2026 | 7.026B |
| November 03, 2026 | 6.973B |
| November 02, 2026 | 6.843B |
| October 30, 2026 | 7.158B |
| October 29, 2026 | 7.050B |
| October 28, 2026 | 7.079B |
| October 27, 2026 | 6.938B |
| October 26, 2026 | 6.869B |
| October 23, 2026 | 6.774B |
| October 22, 2026 | 6.859B |
| October 21, 2026 | 6.999B |
| October 20, 2026 | 6.831B |
| October 19, 2026 | 6.649B |
| October 16, 2026 | 6.614B |
| October 15, 2026 | 6.673B |
| October 14, 2026 | 6.603B |
| Date | Value |
|---|---|
| October 13, 2026 | 6.774B |
| October 12, 2026 | 6.926B |
| October 09, 2026 | 6.739B |
| October 08, 2026 | 6.603B |
| October 07, 2026 | 6.568B |
| October 06, 2026 | 6.642B |
| October 05, 2026 | 6.838B |
| October 02, 2026 | 6.762B |
| October 01, 2026 | 6.758B |
| September 30, 2026 | 6.950B |
| September 29, 2026 | 5.956B |
| September 28, 2026 | 6.031B |
| September 25, 2026 | 5.780B |
| September 24, 2026 | 5.731B |
| September 23, 2026 | 5.718B |
| September 22, 2026 | 5.720B |
| September 21, 2026 | 5.552B |
| September 18, 2026 | 5.421B |
| September 17, 2026 | 5.445B |
| September 16, 2026 | 5.256B |
| September 15, 2026 | 5.291B |
| September 14, 2026 | 5.364B |
| September 11, 2026 | 5.440B |
| September 10, 2026 | 5.536B |
| September 09, 2026 | 5.512B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 698.29B |
| Eli Lilly & Co. | 1.377T |
| Bristol Myers Squibb Co. | 157.63B |
| Xeris Biopharma Holdings, Inc. | 3.162B |
| LENZ Therapeutics, Inc. | -86.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.48M |
| Revenue (Quarterly) | 78.75M |
| Total Expenses (Quarterly) | 107.23M |
| EPS Diluted (Quarterly) | -1.427 |
| Gross Profit Margin (Quarterly) | 83.68% |
| Profit Margin (Quarterly) | -36.17% |
| Earnings Yield | 0.75% |
| Operating Earnings Yield | 0.59% |
| Normalized Earnings Yield | 1.239 |